ASX Health Stocks: Paradigm Bio says drug effective in dogs, HeraMED signs deal in US

• Paradigm Bio says drug is effective in osteoarthritic dogs
• HeraMED signed a deal with Fond, a US-based global SaaS platform
• The first patient has been dosed in Imugene’s clinical trial

Late stage biotech Paradigm Biopharmaceuticals (ASX:PAR) said that its injectable pentosan polysulfate sodium (or iPPS) provided durable improvements in pain, joint function, and cartilage volume compared to placebo.

PAR’s randomised study showed that when osteoarthritic dogs were administered iPPS over 26 weeks, they showed stabilised disease progression at week 8 and week 26.

The 26-week timepoint in the canine model is equivalent to approximately three years in humans, highlighting the durability of positive iPPS treatment effects on osteoarthritis pain, joint structure and function.

This canine study provides consistent evidence, and mirrors the improvements shown in clinical outcomes previously reported from the phase 2 PARA_OA_008 Day 168 results.

“Paradigm will use these canine data in our ongoing discussions with the regulators,” said CEO, Paul Rennie.

HeraMED signs deal with global US

Medtech company HeraMED (ASX:HMD) said a strategic enterprise deal has been signed with Fond, a US-based global SaaS platform that consolidates employee rewards and recognition processes into an easy-to-use solution.

Fond enables employees and managers to recognise each other, redeem rewards, and access exclusive corporate discounts for their corporate members.

The deal will enable Fond to access HeraMED solutions across all Fond’s clients. One of their first customers is an unnamed California-based, global social media company with over 7,000 employees.

Separately, an agreement was also signed with Entrustia Health (part of Refresh Health) to provide the obstetrics and gynaecology medical support.

This is HeraMED’s first agreement in the employer segment which represents an important sales channel going forward.

Imugene doses first patient

Imugene (ASX:IMU) announced the first patient has been dosed in the IMPRINTER study, a clinical trial to evaluate the safety and efficacy of Imugene’s PD1-Vaxx in patients with non-small cell lung cancer (NSCLC).

The study is to determine the safety, efficacy, and optimal dose of PD1-Vaxx in combination with atezolizumab as therapy.

The study will be conducted at sites in USA and Australia.

Share prices today: